Sphere Fluidics appoints Richard Hammond as Chief Technical Officer

Sphere Fluidics appoints Richard Hammond as Chief Technical Officer


Key appointment forms part of ongoing plans to strengthen senior leadership team and support expansion of microfluidic product range for single cell analysis


Cambridge, UK, 13 December 2022: – Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed Richard Hammond as Chief Technical Officer.

In his role as Chief Technical Officer, Richard will be responsible for driving innovation and growing Sphere Fluidics’ product range, including productizing several patented prototypes currently in development. Following expansion of the senior team in May 20211, the appointment demonstrates the Company’s ongoing strategic plans to expand its portfolio of single cell analysis and monoclonality assurance systems to facilitate accelerated biotherapeutic discovery and development.

Richard Hammond, MA MEng, joins Sphere Fluidics with over 20 years’ experience in managing the development of cutting-edge commercial products for healthcare and life sciences. Richard has held numerous senior positions, including leading product and technology development at Alere, Cambridge Consultants and DNA Electronics. With extensive technical expertise, he has worked in cutting-edge research areas, such as automated cell transfection, CAR-T cell therapy manufacture and digital data storage in DNA. Richard holds MA and MEng degrees in engineering from King’s College, University of Cambridge.

Richard Hammond CTO


Richard Hammond, CTO, Sphere Fluidics, commented: “Sphere Fluidics has an excellent reputation for providing world-class products for single cell analysis, and I’m delighted to take the opportunity to build on this further. There is extensive scope for expansion into new, emerging application areas and international markets, and I look forward to working closely with the team to take advantage of this, especially with our outstanding new facilties2.”



Dr Frank F Craig, CEO, Sphere Fluidics, commented “Richard joins us at an exciting time in our international expansion. His expertise will be critical for growth and leadership of our R&D function and design and development of our novel picodroplet-based products. We have an outstanding product portfolio that is continuing to expand to meet customer needs; our systems are designed to simplify and accelerate the study of single cells for pharmaceutical discovery and medical research. All of this will feed into our ambition to become the leader in our field



1. Press release (10th May, 2022): Sphere Fluidics strengthens commercial team with three new senior hires
2. Press release (25th October, 2022): Sphere Fluidics opens new laboratory facilities at Granta Park in Cambridgeshire, UK


For further information please contact:

Sphere Fluidics
Dr. Claire Cox
Tel: +44 7365 209441
Email: claire.cox@spherefluidics.com 

Zyme Communications
Ellie Chandrasma
Tel: +44 (0)7711 232 885
Email: ellie.chandrasma@zymecommunications.com

About Sphere Fluidics www.spherefluidics.com

Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems to enable leading edge research and accelerate biotherapeutic discovery and development.

The Company’s picodroplet incubation technology enables ultra-sensitive, rapid miniaturized assays of target protein secreted from tens of millions of individual cells.

Sphere Fluidics’ Cyto-Mine® System integrates isolation, selective screening, sorting, imaging and clone verification into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value clones to be captured in a single run.

Sphere Fluidics is located in Granta Park and Babraham Research Campus in Cambridgeshire (UK). The Company has also internationalized its business via a global network of distributors.

Follow Sphere Fluidics on Twitter @SphereFluidics and LinkedIn @Sphere Fluidics Limited.